RecruitingNCT06193928
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
Studying Alagille syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Intervention
- Livmarli(drug)
- Enrollment
- 70 enrolled
- Eligibility
- All sexes
- Timeline
- 2023 – 2030
Study locations (8)
- Children's Hospital Los Angeles CHLA, Los Angeles, California, United States
- Section of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics and the Digestive Health Institute, Children's Hospital of Colorado and University of Colorado, Aurora, Colorado, United States
- Children's Healthcare of Atlanta - Emory University School of Medicine, Atlanta, Georgia, United States
- Children's Mercy Kansas City, Department of Gastroenterology, Section of Hepatology, Kansas City, Missouri, United States
- Oregon Health and Science University, Division of Pediatric Gastroenterology, Department of Pediatrics, Portland, Oregon, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Children Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
- University of Utah, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Salt Lake City, Utah, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06193928 on ClinicalTrials.govOther trials for Alagille syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07411716Pediatric Evaluation and Registry for Liver Cholestasis in CanadaChildren's Hospital of Eastern Ontario
- RECRUITINGNCT07293897A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)Takeda
- RECRUITINGPHASE4NCT07290257Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)Mirum Pharmaceuticals, Inc.
- RECRUITINGNCT06850038A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing TreatmentIpsen
- RECRUITINGPHASE3NCT05035030Long-term Safety and Efficacy of Odevixibat in Patients With Alagille SyndromeAlbireo, an Ipsen Company